Company Overview and News

1
VMC / Vulcan Materials Co. (Holding Co.) 8-K (Current Report)

2018-04-12 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) DEF 14A

2018-03-26 sec.gov
DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) DEFA14A

2018-03-26 sec.gov
DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) 8-K (Current Report)

2018-03-16 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) S-3ASR

2018-03-13 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 13, 2018 Registration No. 333-
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) FORM 8-K (Current Report)

2018-03-06 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
Upvote Downvote

2
When Markets Correct, Many Fear, But Few Listen

2018-02-27 seekingalpha
When there’s not much to say, sometimes it’s prudent to not say anything at all. However, due to the volatility over the last month, it seems necessary to break the silence, evaluate what is currently occurring, and put some perspective on what is expected moving forward. Inevitably, when markets correct, something is changing and we ought to try and identify what that is.
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) FORM 8-K (Current Report)

2018-02-26 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2018 VULCAN MATERIALS COMPANY (Exact name of registrant as specified in its charter) New Jersey 001-33841 20-8579133 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) 8-K (Current Report)

2018-02-23 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2018     VULCAN MATERIALS COMPANY (Exact name of registrant as specified in its charter)       New Jersey   001-33841   20-8579133 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) 424B5 (Prospectus)

2018-02-21 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-202769 CALCULATION OF REGISTRATION FEE     Title of Each Class of Securities to be Offered   Maximum Aggregate Offering Price   Amount of Registration Fee(1)(2) Floating Rate Notes due 2021   $500,000,000   $62,250     (1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933. (2) This “Calculation of Registration Fee” table shall be deemed to update the “Calculation of Registration Fee” table in the
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) 8-K (Current Report)

2018-02-20 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2018     VULCAN MATERIALS COMPANY (Exact name of registrant as specified in its charter)       New Jersey    001-33841    20-8579133 (State or other jurisdiction of incorporation)    (Commission File Number)    (IRS Employer Identification No.
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) FWP

2018-02-20 sec.gov
FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus, dated February 20, 2018 Supplementing the Preliminary Prospectus Supplement, dated February 20, 2018 Registration No. 333-202769 Pricing Term Sheet February 20, 2018 This pricing term sheet relates only to the securities described below and should only be read together with the Preliminary Prospectus Supplement, subject to completion, dated February 20, 2018, relating to these securities (the “Preliminary Prospectus Supplement”) and
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) 424B2 (Prospectus)

2018-02-20 sec.gov
424B2 Table of Contents Filed pursuant to Rule 424(b)(2) Registration No. 333-202769   The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Upvote Downvote

 
VMC / Vulcan Materials Co. (Holding Co.) 8-K (Current Report)

2018-02-17 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2018     VULCAN MATERIALS COMPANY (Exact name of registrant as specified in its charter)       New Jersey   001-33841   20-8579133 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

CUSIP: 929160109